Everest Medicines Ltd., a biopharmaceutical company, has expanded its portfolio by subscribing to 15,846,154 American depositary shares of I-Mab, a U.S.-based biotech company specializing in precision immuno-oncology agents. The transaction, valued at approximately US$30.9 million, enhances Everest Medicines' stake in I-Mab to 16.1% of its total issued share capital. This strategic move aligns with Everest Medicines' commitment to advancing novel therapies addressing critical unmet medical needs. The company continues to build its portfolio of first-in-class or best-in-class products, further solidifying its presence in the global biotech industry.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everest Medicines Ltd. published the original content used to generate this news brief on August 01, 2025, and is solely responsible for the information contained therein.